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Abbreviation 30 
AcCoA Acetyl-coA 31 
ALS Amyotrophic Lateral Sclerosis 32 
BMP Bone Morphogenic Protein 33 
Ca
2+
 Calcium 34 
CAT Catalase 35 
Complex I NADH dehydrogenase 36 
Complex I+III NADH-cytochrome c reductase activity 37 
Complex II+III succinate-cytochrome c reductase activity 38 
CS Citrate Synthase 39 
DAPI 4′,6-diamidino-2-phenylindole 40 
DB Decylbenzoquinone  41 
DCFDA 2',7'–dichlorofluorescin diacetate 42 
DDS Deciphering Consortium 43 
DMEM Dulbecco’s modified Eagle’s medium 44 
DTNB 5,5′-dithiobis-2-nitrobenzoic acid 45 
ECM Extra-Cellular Matrix 46 
ExAc Exome Aggregation database  47 
FCCP carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone  48 
GH Growth Hormone 49 
gnomAD Genome Aggregation database  50 
gRNA guide RNA 51 
GRP75 Glucose-Regulated Protein 75 52 
hESC human embryonic stem cell 53 
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hNSC human neural stem cell 54 
hpf hours post fertilization 55 
HPLC High Performance Liquid Chromatography 56 
HSP Hereditary Spastic Paraplegia 57 
IMS Inter-Membrane Space 58 
IUGR Intra-Uterine Growth Restriction 59 
MIM Mitochondrial Inner Membrane 60 
MIT Microtubule Interacting and Trafficking 61 
MOM Mitochondrial Outer Membrane 62 
MPC Mitochondrial Pyruvate Carrier 63 
MTG Mitotracker Green 64 
mΔψ Mitochondrial transmembrane potential  65 
OXPHOS oxidative phosphorylation  66 
PDH Pyruvate Dehydrogenase  67 
pSpCas9n(BB)-2A-GFP Cas9 from S. pyogenes with 2A-EGFP 68 
pSpgRNA S. pyogenes Cas9 guide RNA 69 
RIPA Radioimmunoprecipitation assay 70 
ROH Runs Of Homozygosity  71 
ROS reactive oxygen species 72 
SD standard deviations 73 
SDS-PAGE sodium dodecyl sulfate polyacrylamide electrophoresis 74 
SEM Standard Error of Mean 75 
SNPs Single Nucleotide Polymorphisms 76 
SOD1 Superoxide Dismutase 77 
SOD2 Manganese Superoxide Dismutase 78 
ssODN single stranded oligonucleotide  79 
TBS Tris Buffered Saline 80 
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TMRM Tetramethylrhodamine methyl ester  81 
UPD7 Uniparental disomy 7 82 
WES Whole Exome Sequencing 83 
  84 
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Abstract  85 
Loss-of-function mutations in SPART gene cause Troyer syndrome, a recessive form of spastic 86 
paraplegia resulting in muscle weakness, short stature and cognitive defects. SPART encodes for 87 
Spartin, a protein linked to endosomal trafficking and mitochondrial membrane potential 88 
maintenance. Here, we identified with whole exome sequencing (WES) a novel frameshift mutation 89 
in the SPART gene in two brothers presenting an uncharacterized developmental delay and short 90 
stature. Functional characterization in a SH-SY5Y cell model shows that this mutation is associated 91 
with increased neurite outgrowth. These cells also show a marked decrease in mitochondrial 92 
Complex I activity, coupled to decreased ATP synthesis and defective mitochondrial membrane 93 
potential. The cells also presented an increase in reactive oxygen species, extracellular pyruvate and 94 
NADH levels, consistent with impaired Complex I activity. In concordance with a severe 95 
mitochondrial failure, Spartin loss also led to an altered intracellular Ca
2+ 
homeostasis that was 96 
restored after transient expression of wild-type Spartin. 97 
Our data provide for the first time a thorough assessment of Spartin loss effects, including impaired 98 
Complex I activity coupled to increased extracellular pyruvate. In summary, through a WES study 99 
we assign a diagnosis of Troyer syndrome to otherwise undiagnosed patients, and by functional 100 
characterization we show that the novel mutation in SPART leads to a profound bioenergetic 101 
imbalance. 102 
 103 
  104 
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Introduction 105 
Neurodevelopmental disorders affect 2–5% of individuals and are genetically heterogeneous (1). 106 
They constitute a large proportion of the life-long global health burden in terms of medical care, 107 
hospitalizations, and mortality (2). An example of a rare developmental disorder is Troyer 108 
syndrome (OMIM #275900), which is an autosomal-recessive form of hereditary spastic paraplegia 109 
(HSP) characterized by lower extremity spasticity and weakness, short stature, cognitive defects, 110 
distal amyotrophy and degeneration of corticospinal tract axons (3, 4, 5, 6). In Troyer syndrome 111 
loss-of-function mutations occur in the SPART gene, which codes for Spartin, a multifunctional 112 
protein consisting of a N-terminal Microtubule Interacting and Trafficking (MIT) domain and a C-113 
terminal senescence domain (7, 8) (Supplementary Fig. 1A). Spartin is expressed in a wide range of 114 
tissues at embryonic and adult stages. In the Eurexpress mouse database 115 
(http://www.eurexpress.org) expression of the homologous murine Spg20 was identified in the 116 
nervous and olfactory systems of the developing mouse at embryonic day 14.5 (9). In the Human 117 
Protein Atlas SPART is ubiquitously expressed, with a high expression level in the central nervous 118 
system, gastrointestinal tract and reproductive system 119 
(https://www.proteinatlas.org/ENSG00000133104-SPG20). Spartin functions in a range of cellular 120 
processes including epidermal growth factor receptor trafficking, lipid droplets turnovers, bone 121 
morphogenetic protein (BMP) signalling and cytokinesis (8-14). Specifically, the impaired 122 
cytokinesis in Spg20-/- mice leads to a prominent number of binucleated chondrocytes in 123 
epiphyseal growth plates of bones, accounting for the short stature and skeletal defects observed in 124 
Troyer syndrome (15). 125 
Interestingly, a few studies suggested that Spartin loss might impair mitochondrial function, 126 
documenting alterations in the mitochondrial network and decreases in the mitochondrial membrane 127 
potential (16-19). 128 
In this study we used whole exome sequencing analysis, to identify a novel mutation in SPART 129 
gene in two brothers born from healthy consanguineous parents (first degree cousins). The brothers 130 
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had been referred for pre- and post-natal growth retardation, syndromic short stature and 131 
developmental delay with severe speech impairment, and both carried a homozygous mutation, 132 
c.892dupA, which confers a premature stop codon. Although Troyer syndrome had not been 133 
considered in these two particular cases, a careful re-evaluation identified common features and we 134 
therefore investigated effects of this SPART loss-of-function mutation, which specific focus on 135 
mitochondria. We first evaluated the effects of Spartin loss using gene silencing in human neural 136 
stem cells (hNSCs), documenting altered neuronal growth and exhibited significantly longer 137 
neurites, compared to cells transfected with siRNA. We next generated a neuroblastoma-derived 138 
SH-SY5Y cell line carrying the mutation via CRISPR/Cas9-genome editing. Compared to control 139 
SH-SY5Y cells, the mutant cells exhibited increased neurite outgrowth and altered distribution and 140 
structure of the mitochondrial network. Importantly these cells also showed metabolic changes with 141 
severe decrease in Complex I activity, increased production of mitochondrial reactive oxygen 142 
species (ROS) and elevated extracellular pyruvate, which reflects defective mitochondrial oxidation 143 
of this molecule. Interestingly, in a recent study heterologous expression of human or Drosophila 144 
Spartin extended yeast lifespan, reduced age-associated ROS production and cell death (19). Spartin 145 
localized to the proximity of mitochondria, physically interacting with proteins related to 146 
mitochondrial and respiratory metabolism in yeast (19). Nevertheless, a thorough analysis of human 147 
SPART mutation effects in a human genome-edited neuronal cell model, including a quantitative 148 
mitochondrial respiration and OXPHOS activity assessment, has not been carried out yet. Our novel 149 
findings related to Spartin loss might provide clues to the neurological impairments in Troyer 150 
syndrome. Our data suggest that the mitochondrial impairment could affect neurons by inducing an 151 
energetic failure that could be coupled to excessive ROS production and extended axonal 152 
morphology. 153 
In summary, through a WES study we were able to assign a diagnosis of Troyer syndrome to 154 
otherwise undiagnosed patients, and by functional characterization we elucidated that the novel 155 
mutation in SPART led to a profound bioenergetic imbalance.  156 
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 157 
Patients and methods 158 
Subjects  159 
Two brothers born from consanguineous healthy parents, first-degree cousins of Moroccan origin, 160 
were first evaluated at the Clinical Genetics Unit when they were 42-months and 12-months-old, 161 
respectively. Family history was unremarkable. They both presented with IUGR (intrauterine 162 
growth restriction), stature and weight below -2 SD (standard deviations), relative macrocrania, 163 
dysmorphic features (very long eyelashes, dolichocephaly, prominent maxilla, pectus excavatum) 164 
and mild psychomotor retardation, with severe language delay. They started walking independently 165 
at 18 months. Other shared anomalies included delayed bone age, pes planus, euphoric behavior, 166 
and joint hyperlaxity. The first evaluation did not disclose signs of neuromuscular involvement. 167 
Genetic analyses included: karyotype and analysis of subtelomeric regions, UPD7 and H19 168 
methylation analysis, and mutation screening of PNPLA6 (OMIM#603197), all of which were 169 
negative. 170 
After a 5 years follow-up, the eldest brother (age 8 years and 9 months) gradually developed 171 
muscular hypotrophy in upper and lower limbs, increased muscle tone in the lower limbs 172 
(distal>proximal) and brisk deep tendon reflexes. Sporadic aggressive behavior and inappropriate 173 
crying was reported by parents. The younger sib (6 years and 3 months) developed muscular 174 
hypotrophy as well, mild hyper-reflexia and difficulty to walk on toes or heels. No cerebellar signs 175 
were reported, nor dysarthria/tongue dyspraxia but language impairment remained severe. Stature 176 
was constantly around the 3
rd
 percentile in both sibs. The eldest brother showed a partial Growth 177 
Hormone (GH) deficiency, treated with a GH analogue. 178 
 179 
High-throughput SNP genotyping and Whole Exome Sequencing (WES) 180 
High-Throughput SNP genotyping 181 
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High-throughput SNP (Single Nucleotide Polymorphisms) genotyping was performed on Illumina 182 
Infinium HD Assay Gemini platform (Illumina, San Diego, CA, USA), according to manufacturer’s 183 
protocol, starting from 400 ng of genomic DNA from peripheral blood. Genotypes were converted 184 
into PLINK format with custom scripts. PLINK v1.07 (http://ngu.mgh.harvard.edu/~purcell/plink/) 185 
was used to isolate individual Runs Of Homozygosity (ROH) that showed > 1 Mb overlap between 186 
the three affected siblings (20). 187 
Whole Exome Sequencing (WES) 188 
WES was performed on genomic DNA extracted from peripheral blood (QIAGEN, Hilden, 189 
Germany) from the two affected brothers. Genomic DNA libraries, starting from 100 ng genomic 190 
DNA, were prepared using the Illumina Pair-End Nextera Kit (Illumina) and library was enriched 191 
for exomic sequences using the Nextera coding exome kit. The captured regions were sequenced on 192 
the Illumina HiScanSQ platform for 200 cycles (100 cycles paired-ends, Illumina). The read files 193 
were aligned to hg19 version of the human genome sequencing, annotation and variant 194 
prioritization was performed according to our internal pipeline for exome annotation as previously 195 
reported (21). The identified variants were confirmed by Sanger sequencing. 196 
 197 
Cell lines 198 
SH-SY5Y cells (ATCC, Middlesex, UK) were cultured in Dulbecco’s modified Eagle’s medium 199 
(DMEM; Euroclone, Milan, Italy) supplemented with 10% (v/v) fetal bovine serum, 100 U/mL 200 
penicillin and 100 µg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA). 201 
Human neural stem cells (hNSC), derived from the NIH approved H9 (WA09; WiCell Research 202 
Institute, Madison, WI, USA) human embryonic stem cells (hESCs), were grown in 6-well plates 203 
coated with CTS™ CELLstart™ Substrate (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) 204 
and maintained in KnockOut D-MEM/F-12 with 2mM of GlutaMAX-I supplement, 20 ng/ml of 205 
bFGF, 20 ng/ml of EFG and 2% of StemPro® Neural Supplement (Thermo Fisher Scientific). All 206 
cells were grown in a humidified incubator with 95% air and 5% CO2 at 37°C. 207 
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 208 
Silencing SPART in Neural Stem Cells (hNSC) 209 
To transiently knock-down SPART, hNSC were transfected every 36 hours with a combination of 3 210 
siRNAs (Thermo Fisher Scientific; see Supplementary Table 1 for the sequences), using 211 
Lipofectamine3000 (Thermo Fisher Scientific) according to the manufacturer’s instruction. At day 212 
0, 4 and 8 cells were collected and processed for western blot and imaging analysis. 213 
 214 
Generation of SPART c.892dupA knock-in SH-SY5Y cell line 215 
The SPART mutation was generated in SH-SY5Y genome using guide RNAs (gRNAs) designed 216 
with the CRISPR Design Tool (mit.edu.crispr) (22). Annealed oligos containing the target sequence 217 
for Cas9 were cloned into pSpgRNA that expresses gRNA driven by a U6 promoter (S. pyogenes 218 
Cas9 guide RNA #47108; Addgene, Cambridge, MA, USA, 23) and sequenced. Sequences of 219 
gRNAs and single stranded-oligonucleotide (ssODN) carrying the variant c.892dupA are reported 220 
in Supplementary Table 1. Cells were plated at 80% confluence and transfected with 4.7 µg of 221 
pSpCas9n(BB)-2A-GFP (PX458, #48140; Addgene; 24), 0.8 µg of each gRNA expression plasmid 222 
and 10 M of ssODN with Lipofectamine®3000 (Thermo Fisher Scientific) according to the 223 
manufacturer’s instruction. After 28 hours, cells were sorted with an automated Fluorescence-224 
Activated Cell Sorting (FACS) system (Influx, Becton Dickinson, Franklin Lakes, NJ, USA) and 225 
single cells were plated in 96-well plates coated with Poly-D-Lysine (Sigma-Aldrich). Clones were 226 
amplified and screened by PCR and direct sequencing of the target region. A clone carrying the 227 
specific change and with no off-target mutations was selected for the analysis (hence defined 228 
SPART
892dupA
). The SH-SY5Y clone that underwent the same CRISPR/Cas9 genome editing 229 
approach but did not carry any change was used as control cell line (hence defined SPART
wt
 230 
throughout the text). 231 
 232 
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Western blotting 233 
Cells were lysed in ice-cold RIPA buffer: 50 mM HEPES (EuroClone), 1 mM EDTA (Sigma-234 
Aldrich), 10% glycerol (Thermo Fisher Scientific), 1% Triton X-100 (Sigma-Aldrich), 150 mM 235 
NaCl in the presence of proteases and phosphatases inhibitors (Sigma-Aldrich). Total protein was 236 
measured using the Lowry protein assay kit (Bio-Rad DC Protein Assay; Bio-Rad, Hercules, CA, 237 
USA) according to the manufacturer’s instruction. Protein samples (70 μg) were subsequently 238 
separated on 10% sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE) gels or on 239 
4-20% pre-cast SDS-PAGE gels (Bio-Rad). Gels were then electro-transferred onto nitrocellulose 240 
membranes (Trans-Blot Turbo Transfer System, Bio-Rad). Membranes were blocked in Tris 241 
Buffered Saline (TBS) with 1% Casein (Bio-Rad) for 1 hour at room temperature and incubated 242 
with primary antibodies at 4°C for 16 hours. Membranes were washed three times in Tris-buffered 243 
saline containing 0.1% Tween and incubated with peroxidase-conjugated secondary antibodies for 244 
45 minutes at room temperature. Bands were visualized using WESTAR Supernova (Cyanagen, 245 
Bologna, Italy) and detected with the ChemiDoc™ XRS+ system (Bio-Rad). Densitometric analysis 246 
was performed with ImageLab software (Bio-Rad). Primary antibodies used were: GAPDH (mouse, 247 
1:10,000; Abcam, Cambridge, UK), γ-tubulin (mouse, 1:10,000; Sigma-Aldrich), T-STAT3 248 
(mouse, 1:500; OriGene, Rockville, MD, USA), P-STAT3 (rabbit, 1:500; Cell Signaling, Leiden, 249 
Netherlands), Spartin (rabbit, 1:1,000; 13791-1-AP, N-terminal; ProteinTech, Rosemont, IL, USA) 250 
and GRP75 (goat, 1:500; Santa Cruz, CA, USA). Peroxidase-conjugated secondary antibodies used 251 
were anti-mouse IgG (1:5,000), anti-rabbit IgG (1:5,000; Sigma-Aldrich), anti-goat IgG (1:5,000; 252 
Dako, Glostrup, Denmark). 253 
 254 
Immunofluorescence microscopy 255 
Cells were plated in ibiTreat µ-Slide 8 Well (Ibidi, Martinsried, Germany). When 80% confluent, 256 
they were fixed in 4% paraformaldehyde in PBS for 10 minutes at 4°C. Samples were blocked and 257 
permeabilized in 10% newborn calf serum (Sigma-Aldrich), 0.3% Triton X-100 (Sigma-Aldrich) in 258 
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PBS for 1 hour at room temperature. Samples were incubated 16 hours at 4°C in primary antibody 259 
diluted in 5% newborn calf serum, 0.15% Triton X-100 in PBS. After three 30-minutes washes in 260 
PBS, sample were incubated 16 hours at 4°C in secondary antibodies diluted in 5% newborn calf 261 
serum, 0.15% Triton X-100 in PBS. After three 30-minutes washes in PBS, samples were mounted 262 
in Fluoroshield containing DAPI (4′,6-diamidino-2-phenylindole; Sigma-Aldrich). Microscopies 263 
used for imaging were Leica DM5500B equipped with a Leica DCF3000 G camera (Leica 264 
Mikrosysteme Vertrieb GmbH, Wetzlar, Germany) and Axiovert 200 inverted microscope (Carl 265 
Zeiss, Oberkochen, Germany). Primary antibodies were as follows: α-III tubulin (mouse, 1:500; 266 
Abcam), Spartin (rabbit, 1:1,000; ProteinTech), Nestin (mouse, 1:300; Abcam) and PGP9.5 (rabbit, 267 
1:300; Thermo Fisher Scientific), and secondary antibodies: Alexa Fluor 488 goat anti-rabbit IgG, 268 
Alexa Fluor 488 donkey anti-mouse, Alexa Fluor 555 goat anti-rabbit and Alexa Fluor 555 donkey 269 
anti-mouse (all diluted 1:800; Abcam). Quantitative evaluation of α- tubulin, Spartin and Nestin 270 
fluorescence intensity have been performed using ImageJ. 271 
 272 
RNA isolation and quantitative PCR (qPCR) in cell lines 273 
Total RNA was isolated from SH-SY5Y cultures using the RNeasy Mini Kit (QIAGEN). cDNA 274 
from 1 µg of SPART
wt
 and SPART
892dupA
 RNA was synthesized using the SuperScript™ VILO™ 275 
cDNA Synthesis Kit (Thermo Fisher Scientific). Quantitative PCR was performed using SYBR® 276 
Green master mix (Bio-Rad). All samples were run in triplicate on the ABI7500 Fast PCR machine 277 
(Thermo Fisher Scientific). Melting curve analysis for each primer pair was carried out to ensure 278 
specific amplification. Relative mRNA expression levels of CAT, SOD1, SOD2 were normalized to 279 
the house-keeping gene -actin using the ΔΔCt method. Primers are reported in Supplementary 280 
Table 1. 281 
 282 
Quantification of neurite outgrowth and elongation 283 
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Cells were seeded on Poly-L-Lysine (Sigma-Aldrich) coated glasses and immunofluorescence for 284 
the neuronal marker PGP9.5 was performed as described above. Mean neurite number and length 285 
was measured using the NeuronGrowth plugin (ImageJ, National Institute of Health, Bethesda) by 286 
tracing the individual neurites of cells according to Fanti et al. (25). For each experiment twenty 287 
cells were examined. 288 
 289 
Spheroid formation assay 290 
We generated matrix-free SH-SY5Y spheroid cultures by seeding 2x10
4
 SPART
wt
 and SPART
892dupA
 291 
SH-SY5Y cells in ultra-low attachment µ-slide 8-wells (Ibidi). Cells were grown to allow the 292 
spontaneous formation of spheroids. After 4 days, spheroids were examined and photographed 293 
using an Axiovert 200 inverted microscope (Carl Zeiss), then RNA was extracted. Spheroids 294 
morphology was measured using ImageJ software. 295 
 296 
ROS quantification 297 
Intracellular ROS measurement using DCFDA 298 
Control and SPART
892dupA
 SH-SY5Y cell lines were seeded at 5 x 10
3
 cells/well and incubated 299 
overnight. Cells were treated with 10 µM DCFDA (2',7'–dichlorofluorescin diacetate, Sigma-300 
Aldrich) dissolved in medium for 1 hour. Cells were washed with PBS and the fluorescence 301 
emission from each well was measured (λ Excitation = 485 nm; λ Emission = 535 nm) using a 302 
multi-plate reader (Enspire, Perkin Elmer, Waltham, MA, USA) and normalized for protein content 303 
using a Lowry assay. Data are reported as the mean ± standard deviation of at least three 304 
independent experiments. 305 
Mitochondrial ROS measurement using MitoSOX 306 
Mitochondrial superoxide production was measured using MitoSOX™ Red (Molecular Probes, 307 
Thermo Fisher Scientific) following manufacturer instructions with minor modifications. Briefly, 308 
cells were seeded in 96-well plates (OptiPlate black, Perkin Elmer) at 5 x 10
3
 cells/well and 309 
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incubated for 16 hours to allow adhesion. Cells were then treated with 5 µM MitoSOX Red 310 
dissolved in medium for 30 minutes. Cells were washed twice times with warm PBS and the 311 
fluorescence emission from each well was measured (λ Excitation = 510 nm; λ Emission = 580 nm) 312 
using a multi-plate reader (Enspire, Perkin Elmer) and normalized for protein content using a 313 
Lowry assay. Data are reported as the mean ± standard deviation of at least six independent 314 
experiments. 315 
 316 
Mitochondrial network and morphology assessment via live cell imaging 317 
To visualize the mitochondrial network in live cells, 3×10
4
 cells were plated in ibiTreat µ-Slide 15 318 
Well (Ibidi, Germany) in 50 μl of complete medium and incubated at 37°C in a humidified 319 
atmosphere of 95% air/5% CO2. After 24 hours, cells were transfected with a plasmid carrying the 320 
GFP protein targeted to mitochondria, following the manufacturer’s instructions (CellLight™ 321 
Mitochondria-GFP, BacMam 2.0, Thermo Fisher Scientific). Mitochondrial network morphology 322 
was assessed by live cell imaging, using a Nikon C1si confocal microscope (Nikon, Tokio, Japan) 323 
following the procedure of Dagda et al. (26) with minor modification using ImageJ software. 324 
Briefly, the green channel was subjected to both a background subtraction with a radius of 10 pixels 325 
and a median filter to reduce noise. An automatic threshold value was then applied to delineate the 326 
particles. The mean area/perimeter ratio was employed as an index of mitochondrial 327 
interconnectivity according to the previously published method reported in Dagda et al. (26). 328 
 329 
Mitochondrial three-dimensional (3D) network analysis 330 
In order to visualize the 3D structure of the mitochondrial network, cells were plated in ibiTreat µ-331 
Slide 8 Well (Ibidi, Martinsried, Germany). After 24 hours, cells were transfected with a plasmid 332 
carrying the GFP protein targeted to mitochondria as described above. The mitochondrial 3D 333 
network analysis was performed according to Giuliani et al. (27). Briefly, cell preparations were 334 
scanned with a Nikon Ti-E fluorescence microscope coupled to an A1R confocal system and the 335 
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NIS-Elements AR 3.2 software. An air-cooled argon-ion laser system with 488 wavelength output 336 
was used. Images were acquired with oil immersion (60x) with an optical resolution of 0.18 micron, 337 
3 x scanner zoom, and 1024 x 1024 pixel resolution. All the stacks were collected with optical 338 
section separation (interval) values suggested by the NIS-Elements AR 3.2 software (0.5µm step). 339 
Five randomly selected fields per sample were acquired. 3D images were analyzed by the IMARIS 340 
software (Bitplane, Concord, MA, USA). The software analyzes the volumes of all detected 341 
isosurfaces and calculates the average value, corresponding to the average volume of interconnected 342 
mitochondria per cell. This analysis allows to measure the average volume of single interconnected 343 
mitochondrial isosurfaces, directly linked to mitochondrial fragmentation. 344 
 345 
Mitochondrial oxygen consumption 346 
To measure mitochondrial oxygen consumption in SPART
wt
 and SPART
892dupA
 cells, 1.5x10
6
 cells 347 
for each cell line were harvested at 70-80% confluence, washed in PBS, re-suspended in complete 348 
medium and assayed for oxygen consumption at 37°C using a thermostatically regulated oxygraph 349 
chamber (Instech Mod.203, Plymouth Meeting, PA, USA) in 1.5 ml of culture medium. Basal 350 
respiration was compared with the one obtained after injection of oligomycin (1 μM). FCCP (1–6 351 
μM). Antimycin A (5 µM) was added at the end of experiments to completely block mitochondrial 352 
respiration. The respiratory rates were expressed in μmol O2/min/mg of protein referring to 250 353 
nmol O2/ml of buffer as 100 % at 30°C (28). Data were normalized to protein content determined 354 
using the Lowry assay. 355 
 356 
ATP and ADP determination 357 
Nucleotides were extracted and detected following Jones DP, 1981 (29), using a Kinetex C18 358 
column (250 × 4.6 mm, 100 Å, 5 μm; Phenomenex, CA, USA). Absorbance (260 nm) was 359 
monitored with a photodiode array detector (Agilent 1100 series system). Nucleotide peaks were 360 
identified by comparison and coelution with standards, and quantification by peak area 361 
16 
 
measurement compared with standard curves. The ATP level was also measured in presence or 362 
absence of rotenone (a specific Complex I inhibitor, Sigma-Aldrich). 4x10
5
 SPART
wt
 and 363 
SPART
892dupA 
cells were seeded and treated with 200 nM of rotenone for 72 hours, then ATP level 364 
was measured as describes above. 365 
 366 
Respiratory chain complex activities 367 
Cell lysates were resuspended in a 20 mM hypotonic potassium phosphate buffer (pH 7.5) followed 368 
by spectrophotometric analysis of mitochondrial complexes activity at 37°C using a Jasco-V550 369 
spectrophotometer (Jasco, Easton, MD, USA) equipped with a stirring device. Complex I activity 370 
was measured in 50 mM phosphate buffer at 340nm (ε=6.22 mM −1 cm−1) after the addition of 150 371 
µg of cell lysate, 1 mM KCN, 10 µM antimycin a, 2.5 mg fatty acid-free BSA, 100 µM NADH, 60 372 
µM decylbenzoquinone (DB, Sigma-Aldrich). Complex I (NADH dehydrogenase) specific activity 373 
was obtained by inhibiting complex I with 10 µM rotenone. The succinate-cytochrome c reductase 374 
activity (II+III activity) was measured in 50 mM phosphate buffer at 550 nm (ε=18.5 mM −1 cm−1) 375 
after the addition of 100 µg of cell lysate, 1 mM KCN, 20 mM succinate and 50 µM oxidized 376 
cytochrome c. The specific complex II+III activity was obtained by inhibiting complex II with 500 377 
µM TTFA. The NADH-cytochrome c reductase activity (I+III activity) was measured in 50 mM 378 
phosphate buffer at 550 nm (ε=18.5 mM−1 cm−1) after the addition of 100 µg of cell lysate, 1 mg/ml 379 
of fatty acid-free BSA, 1 mM KCN, 50 µM cytochrome c and 200 µM NADH. The specific 380 
complex I+III activity was obtained by inhibiting complex I with 10 µM rotenone. Citrate synthase 381 
activity was measured in 100 mM TRIS buffer with 0,1% Triton X-100 at 412 nm (ε=13,600 382 
M
−1
cm
−1
) after the addition of 30 µg of cell lysate, 0.1 mM acetyl-CoA, 0.5 mM oxaloacetate, and 383 
0.1 mM 5,5′-dithiobis-2-nitrobenzoic acid (DTNB; Sigma-Aldrich). 384 
 385 
Mitochondrial transmembrane potential (mΔψ) 386 
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Mitochondrial transmembrane potential and mass were measured following Kirk et al. (30) with 387 
minor modifications. Briefly, cells were seeded at the density of 10
4
 cells/well in 96-well culture 388 
plates (OptiPlate Black, Perkin Elmer). After 24 hours, cells were loaded with 50 nM 389 
tetramethylrhodamine methyl ester (TMRM, 544 Excitation; 590 Emission, Thermo Fisher 390 
Scientific) and 25 nM MitoTracker Green (MTG, 490ex; 516em, Thermo Fisher Scientific) for 30 391 
minutes and washed twice with PBS. The fluorescence emission from each well was measured with 392 
a multi-plate reader (Enspire, Perkin Elmer). TMRM fluorescence emission intensity was 393 
normalized by comparing to MitoTracker Green fluorescence. 394 
 395 
NADH quantification 396 
NADH autofluorescence measurements were performed as described by Frezza et al., 2011 (31) 397 
with minor modifications. Briefly, cells were seeded at a density of 3x10
3
 cells/ well in 15-well µ-398 
Slides (Ibidi) following manufacturer’s instructions and incubated for 16 hours to allow adhesion. 399 
Images were collected using a Nikon C1si confocal microscope equipped with UV laser. NADH 400 
quantification was performed using ImageJ software after background subtraction. 401 
 402 
Lactate and pyruvate quantification 403 
Extracellular lactate was determined by HPLC (High Performance Liquid Chromatography). 404 
Briefly, cells were seeded in 6-well dishes and after 72 hours the culture medium was collected for 405 
HPLC analysis. Prior to injection, the culture medium was diluted 1:10 in mobile phase and 406 
centrifuged at 14,000 g for 5 minutes at 4°C. The supernatant was then injected manually into the 407 
HPLC system. Metabolites were separated on a C18 column (Agilent ZORBAX SB-Phenyl, 5 µm, 408 
250×4.6 mm, Santa Clara, CA, USA), using a mobile phase consisting of 50 mM KH2PO4, pH 2.9, 409 
at a flow rate of 0.8 ml/min. Lactate and pyruvate were detected using an Agilent UV detector set to 410 
210 nm and quantiﬁed using Agilent ChemStation software. The retention time was determined by 411 
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injecting standard solution. All injections were performed in triplicate. The peak area was 412 
normalized forprotein content as measured using a Bradford assay. 413 
 414 
Measurement of intracellular Ca
2+
 415 
Intracellular calcium level was assessed in live cells using Fura-2 AM probe (Thermo Fisher 416 
Scientific) following manufacturer’s instruction. The emission of the calcium-free probe was 417 
measured using a Nikon C1si confocal microscope (Nikon, Tokio, Japan) at λ = 380 nm Excitation 418 
and λ = 515 nm Emission. The quantification of fluorescence intensity was carried out using the 419 
ImageJ software, with an automated acquisition of Fura-2 AM probe fluorescence (at least 50 cells 420 
per condition were acquired). 421 
 422 
Rescue of the phenotype with Spartin wild type 423 
Human SPART coding sequence was PCR‐amplified from SH-SY5Y-derived cDNA using the 424 
KAPA HiFi HotStart Taq Polymerase (Kapa Biosystems, Roche Diagnostic, Mannheim, Germany) 425 
according to the manufacturer's instructions. Primers are reported in Supplementary Table 1. The 426 
amplified fragment was digested with XhoI and HindIII (New England Biolabs, Hitchin, UK), 427 
cloned in pcDNA3.1 vector and sequenced to verify the correct insertion. For rescue experiments, 428 
4x10
5
 SPART
wt
 and SPART
892dupA
 cells were plated. The plasmids expressing wild-type SPART (3 429 
μg/experiment) was transfected into SPART892dupA cells using Lipofectamine 3000 (Life 430 
Technologies) following the manufacturer’s instructions. In parallel, the pcDNA3.1 empty vector (3 431 
μg/experiment) was transfected into SPARTwt and SPART892dupA cells. Forty‐eight hours after 432 
transfection, cells were pelleted and washed twice with PBS. Western blot analysis was used verify 433 
Spartin overexpression, determination of ATP and ADP synthesis and assessment of intracellular 434 
Ca
2+
 were performed as previously described. 435 
 436 
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Gene expression of spg20b in zebrafish developmental stages and zebrafish adult tissues 437 
Total RNA from developmental stages between 16–32 cells, up to 120 hours post-fertilization (hpf) 438 
was extracted using the RNeasy Mini kit according to the manufacturer’s instructions (QIAGEN) 439 
using at least 50 embryos at each stage. Heart, liver and brain were dissected from 5 adult fish, 440 
flash-frozen on dry ice and stored at -80°C until the RNA was extracted. Animals were handled 441 
following the guidelines from European Directive 2010/63/EU and euthanised with Schedule 1 442 
procedures of the Home Office Animals (Scientific Procedures) Act 1986. RNA was synthesized 443 
using the SuperScript™ VILO™ cDNA Synthesis Kit (Thermo Fisher Scientific) following the 444 
manufacturer’s protocol. Gene expression level of spg20b was assessed using quantitative PCR 445 
(qPCR) conducted with the SYBR Green master mix (Bio-Rad). All samples were run in triplicate 446 
on the ABI7500 Fast PCR machine (Thermo Fisher Scientific). Relative mRNA expression level of 447 
spg20b was normalized to the eukaryotic translation eef1a1l2 as endogenous control gene. Primers 448 
are reported in Supplementary Table 1. All zebrafish studies were approved by the Animal Welfare 449 
and Ethics Committee at the University of St. Andrews. 450 
 451 
Image analysis 452 
Images were analyzed using ImageJ (public software distributed by the National Institutes of 453 
Health), Chemidoc (Bio-Rad) and IMARIS (Bitplane). 454 
 455 
Statistical analysis 456 
Statistical analysis was conducted with Prism 7 (GraphPad, San Diego, CA, USA). All experiments 457 
were carried out at least in triplicates. Results are expressed as the mean ± SEM. Unpaired 458 
Student’s t-test with Welch’s correction, Fisher’s exact test or ANOVA test with Tukey-multiple 459 
comparison test were used to determine the differences between groups, when appropriate. A p-460 
value <0.05 (two-tailed) was considered statistically significant. 461 
20 
 
 462 
Results 463 
Whole exome sequencing identified a novel loss-of-function mutation in SPART gene 464 
We performed a combined analysis of high-density SNPs genotyping and WES in the two affected 465 
brothers (Fig. 1A: II-1, II-2) born to consanguineous partners. The two siblings presented with a 466 
history of intrauterine growth restriction, stature and weight below -2 SD, relative macrocrania, 467 
dysmorphic features (very long eyelashes, dolichocephaly, prominent maxilla, pectus excavatum, 468 
Fig. 1B) and psychomotor retardation, with severe language delay (for an exhaustive description of 469 
cases see the Materials and Methods section). In consideration of the degree of inbreeding, a search 470 
for runs of homozygosity (ROH) using SNP data from Illumina 350K array identified a region of 471 
homozygosity on chromosome 13 (5 Mb). WES analysis identified a novel insertion on 472 
chr13:g3690561insT (hg19), leading to a c.892dupA (NM_001142294) in the SPART gene (OMIM 473 
*607111). The mutation was homozygous in the two affected sibs and caused a frameshift with the 474 
insertion of a premature stop codon (p.Thr298Asnfs*17) in the protein Spartin. The variant was 475 
carried by the parents (Fig. 1A, I-1 and I-2) and was not present in the Exome Aggregation database 476 
(ExAc) and Genome Aggregation database (gnomAD) (as accessed on 20/11/2018), nor in an in-477 
house whole exome database consisting of 650 exomes. 478 
 479 
Generation of biological models 480 
To understand the effect of SPART ablation we generated two biological models. First, we 481 
transiently silenced SPART with siRNA in human Neural Stem cells (hNSCs), using siRNA specific 482 
to SPART transcripts vs cell treated with scramble siRNA. Silencing efficiency was evaluated using 483 
western blot analysis (Supplementary Fig. 1B). Second, we generated a stable SH-SY5Y cell line 484 
with a knock-in of the c.892dupA mutation using the CRISPR/Cas9 technology.Cells were 485 
transfected with paired gRNAs and Cas9-nickase plasmids and the oligo DNA carrying the 486 
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c.892dupA variant to insert the specific modification into the SH-SY5Y genome (Fig. 1C). The 487 
variant is predicted to generate a shorter protein of 33KDa, however western blot analysis showed 488 
that Spartin in SPART
892dupA
 cells was completely absent (Fig. 1D). 489 
 490 
Spartin depletion affects neuronal morphology leading to neuronal differentiation 491 
To understand the effect of SPART loss on neuronal morphology, we transiently silenced the gene 492 
in hNSCs up to 8 days of treatment, using siRNA specific to SPART transcripts vs scrambled 493 
siRNA (Fig 2A, B). In SPART-silenced hNSCs, we observed an increased neurite outgrowth, 494 
visualized via nestin staining (Fig. 2A, panel f and Fig. 2B, panel a) compared to scramble-treated 495 
hNSCs (Fig. 2A, panel e and Fig. 2B, panel b). After 8 days of SPART silencing, we found no 496 
significant differences in α-tubulin and nestin expression between scramble-transfected and SPART-497 
silenced hNSCs (Student’s t-test with Welch’s correction, p=0.5394 and p=0.9883 respectively, 498 
Supplementary Fig. 1C-D). At day 8, in agreement with western blot data (Supplementary Fig. 1B), 499 
Spartin staining was not detectable in SPART-silenced hNSCs, as compared with those treated with 500 
scrambled siRNA (Student’s t-test with Welch’s correction, p<0.0001, Supplementary Fig. 1E). 501 
In the stable knock-in cell line carrying the c.892dupA mutation, immunostaining for PGP9.5 (a 502 
specific neuronal marker localized to cell bodies and neurites) revealed an altered neuronal 503 
morphology compared to control SPART
wt
 cells (Fig. 2C). SPART
892dupA
 cells showed extensive and 504 
branched neurite-like formations (Fig. 2C, panels g, h) compared to SPART
wt
 (Fig. 2C, panels c, d). 505 
Neuritogenesis was measured using a quantitative evaluation of the length and number of neurites 506 
using the NeuronGrowth software. SPART
892dupA
 cells showed significantly longer neuronal 507 
processes, compared to SPART
wt
 cells (Student’s t-test with Welch’s correction, p=0.0001; 508 
Supplementary Fig. 1F) and an increase in average number of neurites per cell extending from the 509 
cell body (Student’s t-test with Welch’s correction, p=0.0337; Supplementary Fig. 1G). 510 
Moreover, Spartin-depleted cell models (both hNSC and SH-SY5Y) presented an extensive cell loss 511 
compared to controls (Fig. 2D, 2E). 512 
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 513 
Spartin loss alters cell morphology in 3D cultures 514 
Since the data on SPART
892dupA
 cell extended neurites suggested an altered neuronal differentiation, 515 
we evaluated cell morphology in a matrix-free environment. When cells were shifted from a 2D to a 516 
3D micro-environment (spheroids), SPART
wt
 and SPART
892dupA
 cultures showed a different 517 
morphology. Twenty-four hours after seeding both cell lines started to aggregate, and they grew 518 
into spheroids-like structures at 72 hours (Fig. 3A). SPART
wt
 cells formed condensed and 519 
disorganized aggregates (Fig. 3A, panels b, c), whereas SPART
892dupA
 cells formed rounder and 520 
more compact aggregated more similar to spheroids (Fig. 3A, panels e, f). These differences, 521 
already detectable at 24 hours, were confirmed by the quantitative measurement of spheroid 522 
circularity at 24 and 72 hours, using ImageJ software. We found  increased circularity for 523 
SPART
892dupA
-derived spheroids compared to SPART
wt
, both at 24 and 72 hours (Student’s t-test 524 
with Welch’s correction, p<0.0001 and p=0.0001 respectively, Fig. 3B). According to the 525 
classification of Kenny et al. (32), SPART
892dupA
-derived spheroids could be classified as “round 526 
group”, characteristic of non-malignant and more differentiated cells, since there was a prevalence 527 
of rounded spheroids. SPART
wt
-derived spheroids could be classified in the “grape-like” group, 528 
characterized by cancer stem cell-like properties, with high frequency of disorganized formations 529 
(88 round spheroids and 9 grape-like spheroids for SPART
892dupA 
cells vs 11 round spheroids and 55 530 
grape-like spheroids for SPART
wt
 cells; Fisher’s exact test, p<0.0001, Fig. 3C, D). 531 
 532 
Spartin loss alters the mitochondrial network 533 
Previous studies showed that Spartin co-localized with mitochondria and contributed to 534 
mitochondrial stability (16, 18, 33). Therefore, we evaluated the effects of the c.892dupA mutation 535 
on different mitochondrial characteristics. Assessment of mitochondrial network was performed 536 
using live-cell microscopy in mitoGFP-transfected cells (Fig. 4A). The total mitochondrial mass per 537 
cell was similar between SPART
wt
 and SPART
892dupA 
cells (Supplementary Fig. 1H) but decrease in 538 
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the total number of mitochondria was observed in neurite-like extensions in mutants compared to 539 
controls (Fig. 4A, arrows). SPART
892dupA
 cells displayed a fragmented and disorganized 540 
mitochondrial network morphology (Fig. 4A, right panel) compared to control cells (Fig. 4A, left 541 
panel). In particular, we found a decrease of the mean perimeters (Student’s t-test with Welch’s 542 
correction, p=0.0242), mean areas (p=0.0117), and an increase of roundness value (p<0.0001) of 543 
mitochondria in mutant cells compared to controls (Fig. 4B; mitochondria in n=35 cells for each 544 
cell lines were measured). Moreover, mitochondria in SPART
892dupA
 cells exhibited a decreased 545 
interconnectivity, indicated by a decreased area-to-perimeter ratio, compared to the SPART
wt
 546 
control cells (Student’s t-test with Welch’s correction, p<0.0001; Fig. 4C). 547 
In order to further analyze the altered connectivity of the mitochondrial network due to Spartin loss, 548 
we performed a three-dimensional acquisition of mitochondrial-GFP transfected cells with confocal 549 
microscopy. Z-stacks were analyzed using IMARIS software, in order to quantify the mean volume 550 
of the isosurfaces reconstructed from GFP fluorescence and representing the mitochondrial 551 
network. The 3D view of the mitochondrial network emphasized the fragmented organization in 552 
cells lacking Spartin (Fig. 4D). The analysis showed a strong reduction in the mean volume per cell 553 
of the elaborated network, in SPART
892dupA
 compared to SPART
wt
 (Student’s t-test with Welch’s 554 
correction, p=0.0237; Fig. 4E). These data support the hypothesis that Spartin loss might cause 555 
mitochondrial network fragmentation. 556 
 557 
Spartin loss determines a specific OXPHOS Complex I impairment 558 
Mitochondrial morphology reflects its functionality (34), therefore we measured the oxygen 559 
consumption rates in SPART
wt
 and SPART
892dupA 
intact cells, in absence and in presence of the 560 
specific ATPase inhibitor oligomycin A and of carbonyl cyanide-4-(trifluoromethoxy) 561 
phenylhydrazone (FCCP) as uncoupling agent. No difference in endogenous respiration (basal) was 562 
observed, but the uncoupled oxygen consumption (FCCP) was significantly decreased in 563 
SPART
892dupA
 mutant cells (n=3 independent experiments, one-way ANOVA with Tukey's multiple 564 
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comparisons test, p=0.0173; Fig. 5A). We found that cells lacking Spartin exhibited a significantly 565 
lower ATP/ADP ratio in comparison to controls, due to the concomitant decrease of ATP and 566 
increase of ADP levels (n=3 independent experiments, Student’s t-test with Welch’s correction, 567 
p=0.0065; Fig. 5B).We investigated the OXPHOS enzyme activities by measuring: NADH-568 
cytochrome c oxidoreductase activity (Complex I+III); succinate dehydrogenase-cytochrome c 569 
oxidoreductase activity (Complex II+III) and NADH-DB oxidoreductase activity (Complex I). 570 
SPART
892dupA
 mutant cells showed a 50% decrease of Complex I+III and Complex I activities (n=3 571 
independent experiments, Student’s t-test with Welch’s correction, p<0.0001 and p=0.0268 572 
respectively; Fig. 5C, D), whereas no difference compared to controls was found for Complex II+III 573 
activity (p=0.6485; Fig. 5E). These data show that cells lacking Spartin presented a Complex I 574 
impairment. To further investigate the effect of Spartin on Complex I activity, we measured the 575 
ATP level in SPART
wt
 and SPART
892dupA 
grown for 72 hours in the presence and absence of 200 nM 576 
of the specific Complex I inhibitor rotenone. SPART
wt 
cells were significantly impaired in ATP 577 
synthesis in presence of rotenone (n=4 independent experiments, one-way ANOVA with Tukey's 578 
multiple comparisons test, p=0.0077; Fig. 5F), whereas SPART
892dupA 
were less sensitive to 579 
rotenone, since their Complex I activity was already severely impaired by the mutation in SPART 580 
(p=0.5496, Fig. 5F). 581 
Consistently with an impaired OXPHOS Complex I activity, we observed a significant reduction 582 
(20%) in mitochondrial membrane potential in SPART
892dupA 
cells, compared to control cells (n=12 583 
independent experiments, Student’s t-test with Welch’s correction, p<0.0001; Fig. 5G). 584 
 585 
Altered pyruvate metabolism in SPART892dupA mutant cells 586 
Since OXPHOS respiration was impaired, we investigated a possible metabolic switch to 587 
glycolysis. We measured intracellular NADH levels and extracellular lactate. In SPART
892dupA
 588 
mutated cells, the intracellular NADH level was increased in comparison to control cells (13 fields 589 
for each cell type, Student’s t-test with Welch’s correction, p=0.0026, Fig. 6A). HPLC analysis of 590 
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extracellular culture medium did not detect any change in extracellular lactate levels (Fig. 6B). 591 
Nevertheless, in the extracellular culture medium of SPART
892dupA
 cells, we identified a 2.5 folds 592 
increase in pyruvate levels in comparison to controls (n=3 independent experiments, Student’s t-test 593 
with Welch’s correction, SPART892dupA = 231.4±27.65 vs SPARTwt = 77.56±7.639; p=0.0241, Fig. 594 
6C-D). 595 
 596 
STAT3 activation in SPART892dupA mutant cells 597 
Decreased oxidative phosphorylation has been correlated to STAT3 activation, and constitutive 598 
activation of STAT3 in several cell models indicated a major role for this transcription factor in 599 
promoting increased glycolysis (35). Thus, we investigated the phosphorylation/activation status of 600 
STAT3 in mutant and control cell lines using western blot analysis of phosphorylated (p-STAT3) 601 
and total (T-STAT3) STAT3 protein. In SPART
892dupA 
cells STAT3 was phosphorylated, whereas no 602 
activation was observed in SPART
wt 
cells. Comparable levels of total STAT3 were present in both 603 
cell types (Fig. 6E). 604 
 605 
Spartin loss increased mitochondrial Reactive Oxygen Species (ROS) and altered 606 
intracellular Ca
2+
 homeostasis 607 
Increases in cellular superoxide production are implicated in a variety of pathologies, including 608 
neurodegeneration (36). Mitochondrial superoxide is generated as a by-product of oxidative 609 
phosphorylation and in healthy cells occurs at a controlled rate. Given the specific NADH-610 
dehydrogenase activity (Complex I) impairment detected in mutant cells, we investigated whether 611 
ROS production was altered by Spartin loss. Intracellular ROS levels, measured with the 612 
fluorescent probe 2',7'–dichlorofluorescin diacetate (DCFDA), were significantly increased in 613 
SPART
892dupA
 cells (n=3 independent experiments, Student’s t-test with Welch’s correction, 614 
p<0.0001; Fig. 7A). Moreover, by staining live cells with MitoSOX™ Red, a highly selective probe 615 
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for mitochondria-specific superoxide, we found a significant increase in superoxide production in 616 
SPART
892dupA
 cells compared to the control (n=3 independent experiments, Student’s t-test with 617 
Welch’s correction, p<0.0001; Fig. 7B).To further investigate the oxidative stress status of mutated 618 
cells, we tested the expression of the major ROS-detoxifying enzymes. RT-qPCR revealed a 619 
significant reduction in expression of CAT (Catalase), SOD1 (Superoxide Dismutase) and SOD2 620 
(mitochondrial Manganese Superoxide Dismutase) in cells lacking Spartin, compared to controls 621 
(n=3 independent experiments, Student’s t-test with Welch’s correction, p=0.0027 for CAT; 622 
p=0.0280 for SOD1; p=0.0172 for SOD2; Fig. 7C-E, respectively). 623 
Glucose-Regulated Protein 75 (GRP75) has a major role in neuronal cells for mitochondrial 624 
function regulation and protection from stress-induced ROS and physically interacts with Spartin ( 625 
36, 37). Therefore, we evaluated its protein levels, and found a higher expression of GRP75 in 626 
SPART
892dupA
 compared to SPART
wt
 cells (n=3 independent experiments, Student’s t-test with 627 
Welch’s correction, p=0.0327; Fig.7F). 628 
GRP75 also coordinates the exchange and transfer of Ca
2+
, thereby affecting mitochondrial function 629 
and intracellular Ca
2+
 homeostasis (37). Accordingly, we assessed intracellular free Ca
2+
 in 630 
SPART
wt
 and SPART
892dupA
 cells by quantifying Ca
2+ 
probe Fura-2 AM-relative fluorescence. We 631 
found a significant increase of intracellular Ca
2+
 in SPART
892dupA
 cells, compared to SPART
wt
 cells 632 
(n=3 independent experiments, Student’s t-test with Welch’s correction, p<0.0001; Fig. 7G). These 633 
results are consistent with previous data showing that the decreased expression of Spartin via 634 
transient silencing led to a dysregulation of intracellular Ca
2+
 levels (18). 635 
In order to provide additional evidence that these observed defects were specifically due to Spartin 636 
absence, we re-expressed Spartin in SPART
892dupA
 cells. Spartin re-expression in SPART
892dupA
 cells 637 
rescued altered intracellular Ca
2+
, restoring Ca
2+ 
levels as in control cells (n=3 independent 638 
experiments, one-way ANOVA Tukey's multiple comparisons test, SPART
wt
 vs. SPART
892dupA
 639 
p<0.0001; SPART
wt
 vs. SPART
892dupA+ SPART
 p=0.5690; SPART
892dupA
 vs. SPART
892dupA+ SPART 
640 
p<0.0001; Fig. 7H). 641 
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  642 
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Discussion 643 
Next generation sequencing (NGS) technologies are powerful tools for the identification of rare 644 
mutations that cause neurodevelopmental disorders (38-44). The identification of a causative 645 
mutation can support diagnosis, prognosis, and available treatment (45). Using WES technology, 646 
we identified a novel homozygous insertion (c.892dupA) in the SPART gene in two male sibs with 647 
syndromic short stature, developmental delay and severe speech impairment, with consanguineous 648 
healthy parents. This novel SPART mutation generated a frameshift and a premature stop codon in 649 
the Spartin protein. Loss-of-function mutations in SPART cause Troyer syndrome (OMIM 275900), 650 
a very rare recessive form of HSP (3-6). Although Troyer syndrome was not firstly diagnosed, the 651 
WES data prompted a thorough clinical reassessment, that identified muscular hypotrophy in upper 652 
and lower limbs, increased muscle tone in lower limbs (distal>proximal) and brisk deep tendon 653 
reflexes, all symptoms characteristic of this specific HSP form due to mutations in the SPART gene 654 
(46). 655 
Nonetheless, so far very few SPART loss-of-function mutations have been reported (3, 4, 6, 47-51, 656 
Supplementary Table 2). Animal (null mice) and cellular models (Spartin silencing/overexpression) 657 
showed a role for Spartin in different processes, including neuronal survival/sprouting, cell division 658 
and mitochondrial stability (7, 8, 10, 12, 13, 19). 659 
Based on this evidence, we focused our functional studies to investigate the effect of SPART 660 
c.892dupA mutation on mitochondrial network integrity and mitochondrial functionality. We used 661 
two different cell models: hNSCs (silenced for SPART) and SH-SY5Y cell line genome-edited via 662 
CRISPR/Cas9 technology to introduce the mutation c.892dupA. 663 
We found that both hNSCs silenced for SPART and SH-SY5Y cells carrying the SPART loss-of-664 
function mutation presented significant neurite outgrowth/length coupled to extensive cell loss (Fig. 665 
2), in line with the data observed in animal models (14). Gene expression analysis in zebrafish 666 
embryos identified high expression of the SPART homologous (spg20b) through the initial phases, 667 
during cleavage and blastula periods - 0.75-5 hours post fertilization (Supplementary Fig. 2A). In 668 
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adult zebrafish brain, spg20b expression was 18 times higher than in heart and liver tissues 669 
(Supplementary Fig. 2B). 670 
We observed significant changes in the mitochondrial network and significant mitochondrial 671 
fragmentation in absence of Spartin (Fig. 4D-E) with possible detrimental effects on dendrites and 672 
axons during synaptic transmission (52, 53). 673 
In concordance, we observed that SPART
dup892A
 cells presented a mitochondrial impaired respiration 674 
with decreased ATP synthesis specifically due to a decreased Complex I activity (Fig. 5), with a 675 
reduced mitochondrial membrane potential and increased oxidative stress (with concomitant 676 
decreased expression of ROS detoxifying enzymes; Fig. 7). These data demonstrated that Spartin 677 
depletion led to mitochondrial Complex I deficiency. We propose that the mitochondrial 678 
impairments found in SPART
dup892A
 cell possibly contribute to neurodegeneration (Fig. 8A, B). 679 
Perturbations of  mitochondrial dynamics or energetic imbalances underpin many 680 
neurodegenerative disorders, often with overlapping clinical features such as HSP, Alzheimer’s 681 
disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis and Huntington’s disease (54). All 682 
neuronal cellular processes are energy demanding and require significantly active mitochondria. 683 
Moreover, neurons with long axons, such as peripheral sensory neurons and motor neurons, are 684 
more susceptible to neurodegeneration, since they are more sensitive to mitochondrial defects (55). 685 
It is intriguing to note that another form of HSP is due to mutations in spastic-paraplegia-7 gene 686 
(SPG7), encoding for Paraplegin, a protein forming large complexes in the inner membrane of 687 
mitochondria (56, 57). Loss-of-function mutations in SPG7 lead to a defective Complex I assembly 688 
and consequent defective respiratory chain activity (58). Like Paraplegin, Spartin also interacts with 689 
GRP75 (Fig. 8A), a member of mitochondrial complex for the import of nuclear-encoded proteins 690 
into the mitochondria (37). We hypothesize a role for Spartin in assembly or stability of Complex I, 691 
similar to what described for Paraplegin (58). In line with this hypothesis, the increased levels of 692 
GRP75 in SPART mutant cells might indicate a compensatory effect for Spartin absence (Figure 693 
7F). 694 
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In addition to mitochondrial defects, mutant cells presented also specific metabolite imbalances. We 695 
identified for the first time an excess of pyruvate in the context of Troyer syndrome (Fig. 6C). 696 
Pyruvate is directed into mitochondria through the mitochondrial pyruvate carrier (MPC) located in 697 
the mitochondrial inner membrane (MIM). Here, pyruvate functions as fuel input for the citric acid 698 
cycle and for mitochondrial ATP generation. Disruption in pyruvate metabolism affects tissues with 699 
high demand for ATP. The nervous system is particularly vulnerable because of its high demand of 700 
carbohydrate metabolism for ATP generation (59). A previous study in yeast indicated a protective 701 
effect of Spartin overexpression on PDH activity, a key enzyme of glucose metabolism that 702 
converts pyruvate into acetylCoenzyme A (AcCoA) (19). Our study in a human neuronal cell model 703 
identified an increased pyruvate excretion, possibly underlying an impaired pyruvate metabolism, in 704 
absence of Spartin, due to the novel human SPART mutation (Fig. 8A, B). 705 
Furthermore, Spartin loss was associated with a constitutive phosphorylation (hence activation) of 706 
STAT3 (Fig. 6E). STAT3 activation promoted a faster neurite outgrowth (60). Nevertheless, 707 
constitutive STAT3 activation was shown to increase glycolysis and decrease oxidative 708 
phosphorylation, counteracting PDH activity (35). 709 
PDH inhibition has been also reported in presence of oxidative stress (61-63) and decreased 710 
mitochondrial Ca
2+
 levels (64). It is worth noting that the GRP75/VDAC (Voltage-dependent anion 711 
channel) complex regulates mitochondrial Ca
2+
 intake from the endoplasmic reticulum, thereby 712 
affecting mitochondrial function and intracellular Ca
2+ 
homeostasis (37, 65). Consistently, we 713 
observed an increase in intracellular Ca
2+
 in SPART
892dupA
 cells compared to SPART
wt
 cells (Fig. 714 
7G), which was restored to normal levels with the re-expression of Spartin (Fig. 7H). In accordance 715 
to Joshi and Bakowska (18), these results suggest that Spartin loss itself affects trafficking and 716 
buffering cytosolic and mitochondrial Ca
2+
 via GRP75 interaction. 717 
In summary, through a WES study we were able to assign a diagnosis of Troyer syndrome to 718 
otherwise undiagnosed patients and we provided for the first time a thorough assessment of Spartin 719 
mutations in a human neuronal cell model. Functional characterization elucidated that the novel 720 
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mutation in SPART led to a profound bioenergetic imbalance, including impaired Complex I 721 
activity coupled to increased extracellular pyruvate. Our data support the hypothesis that Spartin 722 
coupled with GRP75 might modulate mitochondrial protein import and Ca
2+
 levels, maintaining 723 
low ROS levels and a normal ATP production (Fig. 8A). Spartin loss determines an energetic 724 
failure, due to altered Complex I function, with increased ROS production and altered intracellular 725 
Ca
2+
 possibly leading to reduced PDH activity (59). Therefore, pyruvate is not efficiently converted 726 
into acetyl-coA (AcCoA) and is accumulated and excreted from SPART mutant cells (Fig. 8B). 727 
Hence, we propose that Troyer syndrome due to SPART mutations might be considered a 728 
mitochondrial disease. We propose that the observed neuronal phenotypes result from defective 729 
protein assembly within mitochondria or defective mitochondrial Complex I function, coupled to an 730 
excess of pyruvate and ROS production, generating energetic imbalances that have been already 731 
connected to several neurodegenerative disorders, as mentioned previously (54). As the expansion 732 
of personalized medicine proceeds, with increasing potential for active analyses of genomic data, 733 
the early identification of molecular and genetic defects can lead to a better clinical refinement and 734 
the possibility of applying timely targeted therapies. Most importantly, it is crucial to carry out the 735 
functional characterization of proteins and mutations, to move forward translational work from gene 736 
identification. 737 
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Figure Legends 945 
Figure 1. Identification of SPART c.892dupA variant. (A) Pedigree of the consanguineous 946 
family and electropherograms of the sequences in family members showing the co-segregation of 947 
the change with the spastic paraplegia phenotype. The two sibs are homozygous for the mutation, 948 
whereas both parents are heterozygous carriers. (B) Representative images of patient’s skeletal 949 
defects. Hand X-ray showed a delayed bone age of 1 year at 2 years of chronological age and of 2.5 950 
years at 5.5 years of chronological age. (C) Generation of SPART c.892dupA knock-in SH-SY5Y 951 
cell line. Electropherogram of the SH-SY5Y clone sequence carrying the mutation c.892dupA in 952 
SPART gene and alignment between reference sequence and clone sequence are reported. (D) 953 
Representative western blot of Spartin protein from SPART
wt
 and SPART
892dupA
-SH-SY5Y clone 954 
using a specific anti-Spartin antibody) Western confirmed that in SPART
892dupA
 cells, the predicted 955 
33KDa mutant Spartin is not produced, whereas in control cells Spartin is normally synthesized 956 
with molecular weight of 75-84 KDa. Gamma tubulin was used as endogenous control. 957 
 958 
Figure 2. Spartin depletion affects neuronal morphology and cells growth. (A) Representative 959 
immunofluorescence images showing SPART-silencing in hNSCs. Images showed hNSCs day 0 960 
(not silenced, panels a, d), hNSC scramble day 8 (panels b, e) and hNSC SPART-silenced (panels c, 961 
f). Panel a-c showed immunostaining for Spartin (red), α-tubulin (green) and DAPI (blue). Panels d-962 
f showed immunostaining for Nestin (green) and DAPI (blue). Images showed an increased 963 
neuronal outgrowth in Spartin-depleted hNSCs compared to controls. Scale bars 10 µm. (B) 964 
Photograms in panel a and b are magnifications showing respectively hNSC SPART-silenced and 965 
hNSC scramble cells at day 8, immunostained for Nestin (green) and DAPI (blue). Arrows indicate 966 
neurite extensions that are absent in scramble-treated cells (arrowheads). Scale bars 50 µm. (C) 967 
Representative immunofluorescence images of SPART
wt
 and SPART
892dupA
 SH-SY5H cell lines 968 
stained against the neuronal marker PGP9.5. SPART
892dupA 
cells showed an increased neuronal 969 
morphology compared to SPART
wt
 cells. Scale bars 50µm. Merged images (panels d and h) show at 970 
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higher magnification the insets of the regions in panels c and g, respectively. Arrowheads in panel d 971 
showed the absence of neurites formation in SPART
wt
 cells. Arrows in panel h indicate the neurite 972 
length generation in SPART
892dupA 
cell line. Scale bar 50 µm. (D) Representative images of hNSCs 973 
after 8 days of SPART depletion (panel c, hNSCs siSPART Day 8), showing a strong cell loss 974 
compared to control cells (panel a and b, hNSCs at day 0 and hNSC scramble-transfected at day 8). 975 
Scale bars 10 µm. (E) Representative images showing SPART
wt
 (control) and SPART
892dupA
 cell 976 
lines, showing a strong cell loss in SPART
892dupA
 cells (panel b) compared to control cells (panel a). 977 
Scale bars 50µm. 978 
 979 
Figure 3. Morphological characterization of SPART
892dupA
 spheroids. (A) Morphological 980 
evaluation of SPART
wt 
and SPART
892dupA
-derived spheroids at 24 and 72 hours (panels a, b 981 
representing SPART
wt 
spheres and panels d, e representing SPART
 892dupA 
spheres). Scale bar 20 µm. 982 
Both wild-type and mutant cell lines aggregate at 24 hours and formed spheroids after 72 hours. 983 
Panels c and f showed magnification of the indicated regions in panels b and e. SPART
892dupA
 984 
spheroids were more rounded (panel f) than control SPART
wt
 cells, whereas (panel e) formed more 985 
condensed and disorganized aggregates. (B) Circularity analysis of spheroids performed with 986 
ImageJ at 24 and at 72 hours post seeding. An increased circularity value was observed in 987 
SPART
892dupA
-derived spheroids compared to SPART
wt 
cells at 24 and 72 hours. Unpaired t-test with 988 
Welch’s correction was performed. ****p<0.0001, ***p<0.0001, mean ± SEM. (C) According to 989 
the classification of morphological groups of 3D cell cultures (Kenny et al., 2007). SPART
wt
-990 
derived spheroids meet the criteria for “grape-like”, whereas SPART892dupA-derived spheroids could 991 
be classified as “round”, characteristic of more differentiated cells. (D) Frequency of classification 992 
type for SPART
wt
 and SPART
892dupA 
3D cell cultures derived from N=46 images for SPART
wt 
and 993 
n=38 for SPART
892dupA
. 994 
 995 
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Figure 4. Spartin loss alters mitochondrial morphology and network. (A) Representative z-996 
stack image of mitochondrial network evaluated using mito-GFP probe by live cell imaging. 997 
Control cells showed a more diffused distribution of mitochondria within the cytoplasm of cells, 998 
also in neurites (left panel, arrows). However, SPART
892dupA
 cells showed a notable perinuclear 999 
distribution and absence of mitochondria in neurites (right panel, arrowheads). Scale bars 50 µm. 1000 
(B) Quantitative assessment of mitochondrial interconnectivity measured via live cell imaging 1001 
(n=35 live cells measured for each cell line) using ImageJ Mitochondrial Morphology plugin. 1002 
****p<0.0001, mean ± SEM. (C) Mitochondrial morphology assessment showed decreased mean 1003 
perimeter and mean area and increased roundness value in SPART
892dupA
 vs control cells (*p<0.05, 1004 
****p<0.0001, mean ± SEM). (D) Representative images of 3D z-stacks and relative IMARIS 1005 
reconstruction of the mitochondrial network visualized via mito-GFP transfection in SPART
wt
 and 1006 
SPART
892dupA
 cells. Scale bars: 10 µm. (E) Quantification of mitochondrial network volume 1007 
represented as the mean GFP-isosurface volume per cell (n=5 pictures per group). A significant 1008 
decrease in the mitochondrial isosurface volume was observed in SPART
892dupA
 cells (*p<0.05, 1009 
Student’s t-test).  1010 
 1011 
Figure 5. Spartin loss alters mitochondrial activity. (A) Oxygen consumption rates analysis in 1012 
intact cells in SPART
wt
 (n=3 independent experiments) and SPART
892dupA
 cells (n=3 independent 1013 
experiments). Respiration was measured in DMEM (basal respiration), in presence of oligomycin A 1014 
(non-phosphorylating respiration) and in presence of FCCP (uncoupled respiration). Data were 1015 
normalized on citrate synthase activity. Colour legend: white box= SPART
wt 
cells; black box= 1016 
SPART
892dupA
 cells; white dotted box= SPART
wt 
cells oligomycin A-treated; black dotted 1017 
box=SPART
892dupA 
cells oligomycin A-treated; white striped box= SPART
wt 
cells FCCP-treated 1018 
cells; black striped box= SPART
892dupA 
cells FCCP-treated cells. **p<0.01, mean ± SEM. (B) 1019 
ATP/ADP ratio in cellular extracts from SPART
wt 
and SPART
892dupA 
cells showing a decreased 1020 
ATP/ADP ratio in mutant cells. Bars indicate standard errors. **p<0.01, mean ± SEM. (C-E) 1021 
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OXPHOS complex activity measurements. (C) Complex I+III activity (NADH-cytochrome c 1022 
oxidoreductase activity) in cell homogenate from SPART
wt
 (n=3 independent experiments) and 1023 
SPART
892dupA 
cells (n=3 independent experiments). ****p<0.0001, mean ± SEM. (D) Complex I 1024 
activity (NADH-dehydrogenase) in cell homogenate from wild type (n=3 independent experiments) 1025 
and mutant SHSY-5Y cells (n=3 independent experiments). Data were normalized on citrate 1026 
synthase activity (CS). *p<0.05, mean ± SEM. (E) Complex II+III activity (succinate-cytochrome c 1027 
oxidoreductase activity) in cell homogenate from SPART
wt
 (n=3 independent experiments) and 1028 
SPART
892dupA 
cells (n=3 independent experiments). (F) ATP level in cellular extracts from SPART
wt 
1029 
and SPART
892dupA 
cells grown for 72 hours in the presence and absence of 200 nM rotenone (n=4 1030 
independent experiments) **p<0.01, mean ± SEM. (G) Mitochondrial membrane potential 1031 
measurement assessed with Tetramethylrhodamine (TMRM) probe. The TMRM fluorescence 1032 
emission was normalized on MitoTracker Green emission, (n=12 independent experiments). 1033 
****p<0.0001, mean ± SEM. 1034 
 1035 
Figure 6. Mutant SPART
892dupA 
cells showed an increased NADH level and pyruvate excretion. 1036 
(A) NADH autofluorescence measurement showing an increased level in mutant cells compared to 1037 
controls. **p<0.01, mean ± SEM. (B) Extracellular lactate content determination by HPLC in 1038 
SPART
wt
 and SPART
892dupA
 cells. The extracellular lactate content in culture cell medium was 1039 
quantified after 24 hours of cell growth by HPLC analysis. The peak area corresponding to lactate 1040 
was normalized on cell number. (C) Extracellular pyruvate production SPART
wt
 and SPART
892dupA
 1041 
cells measured by HPLC analysis after 72 hours of cell growth. The peak area corresponding to 1042 
pyruvate was normalized on protein content by Bradford assay. *p<0.05, mean ± SEM. (D) 1043 
Representative HPLC chromatograms of extracellular media from SPART
wt
 and SPART
892dupA
 cells. 1044 
Red line indicates medium from SPART
892dupA
 cells, green line indicates medium only (DMEM high 1045 
glucose) and blue line indicates medium from SPART
wt 
cells. Vertical red line indicates pyruvate. 1046 
(E) Representative western blot analysis showing the expression of phosphorylated and total 1047 
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STAT3 in the two cell lines. Gamma tubulin was used as endogenous control. SPART
892dupA
 showed 1048 
an increase of P-STAT3 compared to SPART
wt 
cells, indicating an over-activation of STAT3 in 1049 
mutant cells. Graph showed the relative quantification of western blot. 1050 
 1051 
Figure 7. Spartin loss increases oxidative stress and alters the homeostasis of calcium. (A) 1052 
Assessment of reactive oxygen species (ROS) production in SPART
wt 
(n=35) and SPART
892dupA
 1053 
(n=35) SH-SY5Y live cells using dichlorofluorescein diacetate (DCFDA) as fluorescent probe. (B) 1054 
Assessment of mitochondrial superoxide production in SPART
wt
 (n=35) and SPART
892dupA
 (n=35) 1055 
SHSY-5Y live cells using MitoSOX Red as specific fluorescent probe. Data were normalized on 1056 
protein content using the Lowry assay. ****p<0.0001, mean ± SEM. (C) CAT, (D) SOD1 and (E) 1057 
SOD2 mRNA relative expression in SPART
wt
 and SPART
892dupA
 cell lines. *p<0.05, **p<0.01, mean 1058 
± SEM. (F) Representative western blot analysis showing the expression of GRP75 protein and the 1059 
relative quantification in the two cell lines. Gamma tubulin was used as endogenous control. 1060 
SPART
892dupA
 showed a higher expression of GRP75 compared to SPART
wt
 cells. *p<0.05, mean ± 1061 
SEM. (G) Representative confocal microscopy images showing SPART
wt
 and SPART
892dupA
 cells 1062 
stained with Fura-2-AM (right panel). Left panel showed quantification of the Ca
2+
-free Fura-2 AM 1063 
relative fluorescence. SPART
892dupA
 (n=50) cells showed an increase of intracellular Ca
2+ 
compared 1064 
to control cells (n=50). ****p<0.0001, mean ± SEM. (H) Representative confocal microscopy 1065 
images of Fura-2 AM showing SPART
wt 
and SPART
892dupA
 cells and re-expression of Spartin in 1066 
mutant cells (right panel). Left panel showed Spartin re-expression evaluated by western blot and 1067 
the quantification of the intracellular-free Ca
2+
 measuring the Fura-2 AM relative fluorescence in 1068 
the three samples. Re-expression of Spartin rescued the intracellular Ca
2+
 concentration. 1069 
****p<0.0001, Data are reported as the mean ± SEM of at least three independent experiments. 1070 
 1071 
Figure 8. Model of Spartin functions in mitochondrial metabolism. (A) Spartin interacts with 1072 
GRP75, modulating the import of mitochondrial proteins encoded by the nucleus via the TIM-TOM 1073 
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complexes into the mitochondria (Milewska et al., 2009), allowing a normal ATP production 1074 
through Krebs’s cycle and OXPHOS activity (Complex I-V). (B) Spartin loss, as observed in our 1075 
experimental settings, determines an energetic failure due to an altered Complex I activity, with a 1076 
decreased ATP production, and a halt in mitochondrial oxidative phosphorylation leading to 1077 
decreased mitochondrial membrane potential, and increased oxidative stress, due to enhanced 1078 
production of mitochondrial ROS. Increased oxidative stress/increased ROS are known inhibitors of 1079 
PDH activity (Gray et al., 2014). Moreover, Spartin loss results in a reduction of mitochondrial 1080 
Ca
2+
 levels (Joshi and Bakowska, 2011) which could alter the activity of PDH. Accordingly, we 1081 
observed that pyruvate, which enters in mitochondria through the mitochondrial pyruvate carrier 1082 
(MPC), was not efficiently converted into acetyl-coA (AcCoA), Krebs’s cycle substrate, thus 1083 
accumulating and excreted from SPART
892dupA
 mutant cells. Therefore, we hypothesize that the 1084 
energetic failure observed in absence of Spartin, probably related to an impaired mitochondrial 1085 
protein import of the nuclear-encoded subunits, is pivotal in generating the neurodegenerative 1086 
defects observed in neurons in Troyer syndrome. 1087 
Abbreviations: MPC, mitochondrial pyruvate carrier; PDH, pyruvate dehydrogenase; Δψ, 1088 
mitochondrial membrane potential; MOM, mitochondrial outer membrane; MIM, mitochondrial 1089 
inner membrane; IMS, inter-membrane space; ECM, extracellular matrix. I-V: mitochondrial 1090 
OXPHOS complexes; TOM, translocase of the outer membrane; IP3R, Inositol trisphosphate 1091 
receptor, Phosphatidylinositol 3-phosphate; VDAC, Voltage-dependent anion-selective channel. 1092 
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Supplementary Tables 1 
Supplementary Table 1. Primer sequences for Sanger sequencing of WES mutation in SPART, 2 
gRNA sequences, DNA donor oligo and primers for RT-qPCR are reported. 3 
Primer Sequence 
SPARTx3F TGTTTCCAACTTTGAAGTGTTTATTT 
SPARTx3R CAATTTCTCTAAAAGCTGAAGTGC 
SPART_gRNA-A_1 CACCGCCCGCAGTACATTTCAGAAC 
SPART_gRNA-A_2 AAACGTTCTGAAATGTACTGCGGGC 
SPART_gRNA-B_1 CACCGACAAGCAGCAGGATGCTTTG 
SPART_gRNA-B_2 AAACCAAAGCATCCTGCTGCTTGTC 
ssODN_SPART_c.892dupA GTTTGTGACTGGTTATATCCTCTAGTT 
CCTGATAGATCTCCGGTTCTGAAATGT 
ACTGCGGGAGCCTACATGTTTCCTGAT 
AACAATGCTACAAGCAGCAGGATGCTTT 
GTGGGGGTCGTCCTGTCCTCTGAGTTACC 
AGAGGATGATAGAGAGCTCTTTGAG 
CAT_qPCR_F TAAAGGAGCAGGGGCCTTTGGC 
CAT_qPCR_R GGGAGTCTTCTTTCCAATATGCT 
SOD1_qPCR_F AATACAGCAGGCTGTACCAGT 
SOD1_qPCR_R AGTCTCCAACATGCCTCTCTTC 
SOD2_qPCR_F GTTGGCCAAGGGAGATGTTACA 
2 
 
SOD2_qPCR_R TTAGGGCTGAGGTTTGTCCA 
SOD3_qPCR_F CGCTACTGTGTTCCTGCC 
SOD3_qPCR_R GTACATGTCTCGGATCCACTC 
hActII_qPCR_F CCTGGCACCCAGCACAAT 
hActII_qPCR_R GGGCCGGACTCGTCATACT 
eef1a1l2 Fw TTGAGAAGAAAATCGGTGGTGCTG 
eef1a1l2 Rv GGAACGGTGTGATTGAGGGAAATTC 
spg20b Fw CTTTCTCCAGGTTTGTGACTGG 
spg20b Rv ATCATGTCGGGGAACATGTAGA 
SPG20_HindIII Fw GAGAGAAAGCTTATGGAGCAAGAGCCACAAAATATG 
SPG20_XhoI Rv GAGAGACTCGAGTCATTTATCTTTCTTCTTTGCCTCC 
 4 
Supplementary Table 2. Mutations reported in SPART in Troyer syndrome. 5 
References Mutation Transcript 
Manzini et al., 2010 
Tawamie et al., 2015 
Butler et al., 2016 
c.1110delA 
(p.Lys369fs*29) 
NM_001142294 
Patel et al., 2002 
Bakowska et al., 2008 
c.364_365delAT 
(p.Met122Valfs*) 
NM_001142294 
Bizzarri et al., 2017 c.1324G>C 
(p.Ala442Pro) 
NM_001142294 
Dardour et al., 2017 c.1369C>T 
(p.Arg457*) 
NM_001142294 
3 
 
present paper (Diquigiovanni et al.) c.892dupA 
(p.Thr298Asnfs*17) 
NM_001142294 
 6 
 7 
Supplementary Figure Legends 8 
Supplementary Figure 1. Spartin protein analysis in neural cell models. (A) Representative 9 
image of Spartin protein showing the Microtubule Interacting and Trafficking domain (MIT) (aa 10 
16-94) and the senescence domain (aa 427-611). The mutation identified in the two brothers is 11 
indicated by an arrow (duplication of nucleotide 892 at amino acid 298 to truncate the 666-amino 12 
acid long protein at amino acid 315). (B) Representative western blot of Spartin protein after gene 13 
silencing in hNSCs. First lane: hNSC lysed at day 0; second lane: untransfected hNSCs lysed at day 14 
4; third lane: hNSCs transfected with scramble siRNAs lysed at day 4; forth lane: hNSCs 15 
transfected with siRNAs specific to SPART transcripts lysed at day4; fifth lane: untransfected 16 
hNSCs lysed at day 8; sixth lane: hNSC transfected with scramble siRNAs lysed at day 8; seventh 17 
lane: hNSCs transfected with siRNAs specific to SPART transcripts lysed at day 8. The image 18 
showed the complete absence of Spartin protein after 4 and 8 days of silencing. Gamma tubulin was 19 
used as reference. (C-E) Quantitative analysis of alpha-tubulin, nestin and Spartin immunolabeling 20 
in cell treated with scramble siRNA and with siRNA specific to SPART transcripts. Quantification 21 
of the average intensity with background subtraction was performed with ImageJ and at least 10 22 
cells were analysed. Data are represented as mean ± SEM, ****p<0.0001. (F-G) Quantitative 23 
analysis of neurite length and neurite number respectively. SPART
892dupA
 mutant cells (n=20) 24 
showed a strong increase in the number of neurites per cell and in their length compared to SPART
wt
 25 
(n=20). ***p<0.0001; *p<0.05, mean ± SEM. (H) Mitochondrial mass measurement with mito-26 
GFP probe in live-cells. Fluorescence signal was quantified using ImageJ standard tools. Values are 27 
reported as mean ± SEM. *p<0.01. 28 
 29 
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Supplementary Figure 2. Gene expression analysis in zebrafish. (A) Gene expression analysis of 30 
spg20b gene at different zebrafish developmental stages, spanning from 16–32 cells, up to 120 31 
hours post-fertilization (hpf). A very high spg20b expression was identified at the 16–32 cells and 32 
3–5 hpf stages (including cleavage and blastula periods), suggesting an important role for Spartin in 33 
these initial developmental phases. Representative optical images of zebrafish embryos/larvae 34 
morphology at each development stages are shown. (B) Gene expression analysis of spg20b gene in 35 
zebrafish adult heart, liver and brain tissues. We observed a spg20b expression 18 folds times 36 
higher in brain compared to liver and heart. ****p<0.0001, mean ± SEM. 37 
 38 
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Supplementary Table 1. Primer sequences for Sanger sequencing of WES mutation in SPART, 2 
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Supplementary Figure 1. Spartin protein analysis in neural cell models. (A) Representative 9 
image of Spartin protein showing the Microtubule Interacting and Trafficking domain (MIT) (aa 10 
16-94) and the senescence domain (aa 427-611). The mutation identified in the two brothers is 11 
indicated by an arrow (duplication of nucleotide 892 at amino acid 298 to truncate the 666-amino 12 
acid long protein at amino acid 315). (B) Representative western blot of Spartin protein after gene 13 
silencing in hNSCs. First lane: hNSC lysed at day 0; second lane: untransfected hNSCs lysed at day 14 
4; third lane: hNSCs transfected with scramble siRNAs lysed at day 4; forth lane: hNSCs 15 
transfected with siRNAs specific to SPART transcripts lysed at day4; fifth lane: untransfected 16 
hNSCs lysed at day 8; sixth lane: hNSC transfected with scramble siRNAs lysed at day 8; seventh 17 
lane: hNSCs transfected with siRNAs specific to SPART transcripts lysed at day 8. The image 18 
showed the complete absence of Spartin protein after 4 and 8 days of silencing. Gamma tubulin was 19 
used as reference. (C-E) Quantitative analysis of alpha-tubulin, nestin and Spartin immunolabeling 20 
in cell treated with scramble siRNA and with siRNA specific to SPART transcripts. Quantification 21 
of the average intensity with background subtraction was performed with ImageJ and at least 10 22 
cells were analysed. Data are represented as mean ± SEM, ****p<0.0001. (F-G) Quantitative 23 
analysis of neurite length and neurite number respectively. SPART
892dupA
 mutant cells (n=20) 24 
showed a strong increase in the number of neurites per cell and in their length compared to SPART
wt
 25 
(n=20). ***p<0.0001; *p<0.05, mean ± SEM. (H) Mitochondrial mass measurement with mito-26 
GFP probe in live-cells. Fluorescence signal was quantified using ImageJ standard tools. Values are 27 
reported as mean ± SEM. *p<0.01. 28 
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Supplementary Figure 2. Gene expression analysis in zebrafish. (A) Gene expression analysis of 30 
spg20b gene at different zebrafish developmental stages, spanning from 16–32 cells, up to 120 31 
hours post-fertilization (hpf). A very high spg20b expression was identified at the 16–32 cells and 32 
3–5 hpf stages (including cleavage and blastula periods), suggesting an important role for Spartin in 33 
these initial developmental phases. Representative optical images of zebrafish embryos/larvae 34 
morphology at each development stages are shown. (B) Gene expression analysis of spg20b gene in 35 
zebrafish adult heart, liver and brain tissues. We observed a spg20b expression 18 folds times 36 
higher in brain compared to liver and heart. ****p<0.0001, mean ± SEM. 37 
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